WilmerHale Represents Akouos in Acquisition by Lilly

WilmerHale Represents Akouos in Acquisition by Lilly

Client News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.

On October 18, 2022, Eli Lilly and Company announced a definitive agreement for Lilly to acquire Akouos, a precision genetic medicine company that is developing a portfolio of first-in-class adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss. Akouos was founded in 2016 by leaders in the fields of neurotology, genetics, inner ear drug delivery and AAV gene therapy. The acquisition will enable the company to leverage Lilly's resources and global reach to further its mission of making healthy hearing available to all. Under the terms of the agreement, Lilly will commence a tender offer to acquire outstanding shares of Akouos for an aggregate purchase price of approximately $487 million.

The WilmerHale team representing Akouos was led by Rosemary G. Reilly, Joseph Conahan, Andrew Bonnes, Molly Fox, Will Myer, Erin Garrity and Chris Gravallese.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel